Logos Capital logo

Logos Capital

North America, California, United States, San Francisco

Description

Logos Capital is a fundamental biotechnology-focused investment fund.

Investor Profile

Logos Capital has made 129 investments, with 12 in the past 12 months and 4% as lead.

Stage Focus

  • Series B (38%)
  • Post Ipo Equity (23%)
  • Series C (19%)
  • Series A (14%)
  • Series D (2%)
  • Series Unknown (2%)
  • Series E (1%)
  • Seed (1%)
  • Series G (1%)

Country Focus

  • United States (90%)
  • Canada (3%)
  • China (3%)
  • United Kingdom (2%)
  • Singapore (1%)
  • Ireland (1%)
  • Denmark (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
  • Life Science
  • Oncology
  • Biopharma
  • Health Diagnostics
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Logos Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 33
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 25
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 57
CA
North America, Massachusetts, United States, Boston
Co-Investments: 40
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 22
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 32
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 48
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 28
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 55
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 23

Which angels does Logos Capital often collaborate with?

NB
North America, California, United States, Menlo Park
Shared Deals: 1
ER
North America, California, United States, San Francisco
Shared Deals: 1
G"
North America, California, United States
Shared Deals: 1
SK
North America, California, United States, Los Angeles
Shared Deals: 1
SL
North America, California, United States, San Francisco
Shared Deals: 1
KP
North America, California, United States, San Francisco
Shared Deals: 1
RK
North America, California, United States, Los Angeles
Shared Deals: 1
AA
North America, California, United States, San Francisco
Shared Deals: 1
TB
North America, California, United States, Los Altos
Shared Deals: 1
HS
North America, California, United States, Redwood City
Shared Deals: 1

What are some of recent deals done by Logos Capital?

Aviceda Therapeutics

Cambridge, Massachusetts, United States

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series CJan 7, 2025
Amount Raised: $207,500,000
Trevi Therapeutics

Sandy Hook, Connecticut, United States

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityDec 16, 2024
Amount Raised: $50,000,000
Maze Therapeutics

South San Francisco, California, United States

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

BiopharmaBiotechnologyGeneticsTherapeutics
Series DDec 3, 2024
Amount Raised: $115,000,000
35Pharma

Montreal, Quebec, Canada

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

BiopharmaBiotechnologyPharmaceutical
Series CNov 26, 2024
Amount Raised: $53,000,000
ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series BNov 25, 2024
Amount Raised: $135,000,000
Aclaris Therapeutics

Malvern, Pennsylvania, United States

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

BiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityNov 18, 2024
Amount Raised: $80,000,000
858 Therapeutics

San Diego, California, United States

858 Therapeutics develops small molecule drugs targeting oncology and immunology.

BiotechnologyHealth CarePharmaceutical
Series BSep 26, 2024
Amount Raised: $50,000,000
Elektrofi

Boston, Massachusetts, United States

Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.

Alternative MedicineBiotechnologyTherapeutics
Series CAug 22, 2024
Amount Raised: $112,250,000
Third Arc Bio

Boston, Massachusetts, United States

Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.

BiotechnologyHealth CareLife ScienceMedicalOncology
Series AJul 23, 2024
Amount Raised: $165,000,000
Scorpion Therapeutics

Boston, Massachusetts, United States

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

BiotechnologyHealth CareLife ScienceOncologyPrecision Medicine
Series CJul 16, 2024
Amount Raised: $150,000,000